Interim report January-March 2013

FIRST QUARTER

• Sales increased by 23 percent in local currency. Sales were the highest ever for an individual quarter and amounted to SEK 16.3 (13.8*) million, corresponding to an increase of 18 percent in SEK.

• Operating income before depreciation and amortization (EBITDA) amounted to SEK 3.8 (5.0*) million, corresponding to an EBITDA margin of 23 percent.

• Net income amounted to SEK 2.4 million, resulting in earnings per share of SEK 0.12.

• Cash flow from operating activities was SEK 4.0 million.

• In late March, the FDA responded with further supplementary questions regarding the application for marketing approval of STEEN Solution™ on the American market. Xvivo plans to have its formal response to these questions submitted by the end of April/beginning of May.

• The clinical study in the USA is proceeding according to plan with good clinical results. 36 of a planned 42 patients had received transplants by the end of the period. The company expects the study to be completed during the second quarter 2013.

• There continues to be a great deal of interest from clinics in the USA.

• Storage and distribution of products for Europe/Asia has now been taken over by the company’s own organization.

• The sales and marketing organization has been enhanced with the appointment of a global sales and marketing director and a regional manager for Europe.

April 19, 2013
Gothenburg

XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO

* Comparative figures for 2012 are Vitrolife’s Transplantation segment such as it was reported in Vitrolife’s reporting